bioAffinity Technologies' CyPath® Lung Test to be Highlighted at Cleveland Clinic Symposium for Early Lung Cancer Detection
bioAffinity Technologies, Inc. is set to feature its CyPath® Lung test at the Cleveland Clinic's 'Advances in Early Lung Cancer Detection' symposium on April 16, 2026. The event, which is invitation-only, will focus on the latest developments in lung cancer risk assessment and early detection technologies. Dr. Gordon Downie, the Chief Medical Officer of bioAffinity Technologies, will participate in a panel discussion on lung nodule management. The CyPath® Lung test is a noninvasive diagnostic tool that uses flow cytometry and artificial intelligence to detect cancerous cells in sputum samples. It has demonstrated high sensitivity and specificity in identifying lung cancer in high-risk patients, particularly those with small indeterminate lung nodules. The symposium aims to bring together global leaders in lung cancer research and treatment to discuss emerging technologies and methods for early cancer detection. 
